FC
FOLD

Finepoint Capital’s Amicus Therapeutics FOLD Stock Holding History

Finepoint Capital’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,489,025
Closed -$21.1M – 27
2023
Q4 		$21.1M Hold
1,489,025
– – 6.67% 4
2023
Q3 		$18.1M Buy
1,489,025
+163,250
+12% +$2.11M 9.02% 2
2023
Q2 		$16.7M Sell
1,325,775
-134,400
-9% -$1.59M 5.76% 5
2023
Q1 		$16.2M Buy
1,460,175
+31,700
+2% +$391K 6.19% 9
2022
Q4 		$17.4M Sell
1,428,475
-259,925
-15% -$2.93M 5.64% 6
2022
Q3 		$17.6M Sell
1,688,400
-322,500
-16% -$3.59M 5.8% 9
2022
Q2 		$21.6M Buy
+2,010,900
New +$16.6M 7.47% 2

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Finepoint Capital's FOLD Position: Q1 2024 in Review

Finepoint Capital sold out of Amicus Therapeutics (FOLD) in Q1 2024, closing a stake of 1,489,025 shares — an estimated $21.1M sold.

Finepoint Capital first reported a position in FOLD in Q2 2022 and held it in 7 quarters. The position peaked at $21.6M in Q2 2022. 254 funds tracked by Wall St. Rank hold FOLD as of Q1 2024.

  • Finepoint Capital reported no remaining Amicus Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Finepoint Capital sold 1,489,025 Amicus Therapeutics shares in Q1 2024, an estimated $21.1M.
  • Finepoint Capital first reported a position in Amicus Therapeutics in Q2 2022 and held it in 7 quarters.
  • Finepoint Capital's Amicus Therapeutics position peaked at $21.6M in Q2 2022.
  • 254 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2024.

Based on Finepoint Capital's 13F filing for Q1 2024, filed 14 May 2024.